News >

Expert Highlights Precision Medicine Advances in GI Cancers

Caroline Seymour
Published: Wednesday, Mar 21, 2018

Eric A. Collisson, MD

Eric A. Collisson, MD
The availability of targeted agents and immunotherapy in gastrointestinal (GI) cancers is enabling physicians to address more molecular aberrations, such as high mutation rates and defects in homologous recombination, says Eric A. Collisson, MD.

Collisson noted, however, that while tremendous progress has been made, much remains unknown about optimizing genomic testing and implementing precision medicine in GI malignancies.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication